Clinical Trial

MELCAYA - Novel Health Care Strategies for Melanoma in Children, Adolescents, and Young Adults - Work Package 3 (WP3)

Study acronym: Mol-Mel
Recruiting
View on ClinicalTrials.gov →
Summary
The aim of this study is to investigate a type of skin cancer, also known as melanoma, in children, adolescents, and young adults, who will be referred to as CAYA patients in this project. The need for this study arises because this disease, in CAYA patients, is still poorly understood due to its rarity in individuals under 30 years old. This often leads to difficulties in assessing its severity and, consequently, in deciding on the necessary treatments to ensure the patient\'s recovery. The goal of this study is to examine melanoma in CAYA patients in order to gather the information needed to provide better diagnoses for affected patients and, as a result, select appropriate treatments to fight the disease and promote the patient\'s full recovery. Additionally, the data collected will be used to create a Pan-European online platform that will allow doctors across the European Union to consult the obtained data and collaborate on particularly complex melanoma cases, always with the aim of ensuring the patient\'s full recovery in the shortest possible time.
Trial Details
NCT Number NCT06602648
Lead Sponsor University of Florence
Collaborators: Tubingen University Hospital, Maria Sklodowska-Curie National Research Institute of Oncology, Fondazione IRCCS ISTITUTO NAZIONALE TUMORI, Hospital Clinic of Barcelona, Istanbul University, University Of Perugia, German Cancer Research Center
Conditions Melanoma of Skin
Enrollment 100 participants
Start Date 2024-04-17
Primary Completion 2026-11 (estimated)
Study Completion 2026-11 (estimated)
Updated on ClinicalTrials.gov 2024-09-19